6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-indazole-3-carbaldehyde | 1221178-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-indazole-3-carbaldehyde
• 英文别名: 6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)indazole-3-carbaldehyde；1-(oxan-2-yl)-6-phenylmethoxyindazole-3-carbaldehyde
• CAS: 1221178-90-0
• 化学式: C₂₀H₂₀N₂O₃
• 分子量: 336.39
• InChiKey: KQADXPMEBXMJDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-indazole-3-carbaldehyde 在 盐酸 、 水 、 sodium acetate 、 三甲基乙酰氯 、 sodium hydride 、 三乙胺 、 对甲苯磺酰肼 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 水 、 mineral oil 为溶剂， 反应 26.92h， 生成 3-(6-(Benzyloxy)indazol-3-yl)-N,N-dimethylpropanamide
  参考文献：
  名称：

  EP2484668

  摘要：

  公开号：
• 作为产物：
  描述：

  (6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-indazol-3-yl)methanol 在 manganese dioxide 正己烷 、 乙酸乙酯 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 16.0h， 以the title compound (1.20 g) was obtained的产率得到6-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-indazole-3-carbaldehyde
  参考文献：
  名称：

  INDAZOLE ANALOG

  摘要：

  【目的】提供一种选择性刺激β3-肾上腺素能受体的药物，特别是一种能够优先刺激β3-肾上腺素能受体而非α1-肾上腺素能受体的药物。该药可以用于糖尿病、肥胖症、高脂血症、抑郁症、胆石症、胆道高动力症引起的疾病、胃肠道高功能引起的疾病、间质性膀胱炎、过度活动的膀胱或尿失禁、伴有泪液减少的疾病等的治疗和预防。 【解决方案】一般式（I）所代表的吲唑类似物或其盐。包含这些吲唑类似物或其盐作为活性成分的药物。

  公开号：

  US20120225909A1

文献信息

• INDAZOLE COMPOUNDS
  申请人：Nakano Seiji

  公开号：US20100160256A1

  公开（公告）日：2010-06-24

  Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

  提供的是以下公式（A-1）和公式（1）所代表的化合物，或其盐。公式（A-1）和公式（1）的化合物或其盐具有133肾上腺素受体激动剂活性，因此可作为治疗和预防糖尿病、肥胖、高脂血症、抑郁症、胆石症或胆道高动力性疾病、消化系统过度活动引起的疾病、间质性膀胱炎、膀胱过度活动或尿失禁的药物，或作为治疗和预防伴随眼泪减少的疾病的药物。
• INDAZOLE DERIVATIVES
  申请人：NAKANO Seiji

  公开号：US20100152265A1

  公开（公告）日：2010-06-17

  Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

  提供由化学式（A-1）和化学式（1）或其盐表示的化合物。由化学式（A-1）和化学式（1）或其盐表示的化合物具有β3肾上腺素能受体激动剂活性，因此可用作预防和治疗糖尿病、肥胖症、高脂血症、抑郁症、胆结石、胆道过度活动引起的疾病、消化道过度活动引起的疾病、间质性膀胱炎、膀胱过度活动、尿失禁或泪液分泌减少引起的疾病等。
• Indazole derivatives
  申请人：Asahi Kasei Pharma Corporation

  公开号：US08304443B2

  公开（公告）日：2012-11-06

  Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

  提供由化学式（A-1）和化学式（1）或其盐所表示的化合物。这些由化学式（A-1）和化学式（1）或其盐所表示的化合物具有β3肾上腺素能受体激动剂活性，因此可用作预防和治疗糖尿病、肥胖症、高脂血症、抑郁症、胆石症、胆道高活性疾病、消化道高活性疾病、间质性膀胱炎、膀胱过度活动、尿失禁或泪液分泌减少等疾病的药物。
• INDAZOLE DERIVATIVE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2351742A1

  公开（公告）日：2011-08-03

  Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

  提供了由式（A-1）和式（1）或其盐代表的化合物。由式（A-1）和式（1）或其盐代表的化合物具有β3肾上腺素能受体激动剂活性，因此可用作预防和治疗糖尿病、肥胖症、高脂血症、抑郁症、胆道结石、胆道活动亢进引起的疾病、消化道活动亢进引起的疾病、间质性膀胱炎、膀胱过度活动症、尿失禁或泪液分泌减少引起的疾病等的药物。
• INDAZOLE COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2345644A1

  公开（公告）日：2011-07-20

  Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

  本发明提供了由下式（A-1）和式（1）代表的化合物或其盐。式（A-1）和式（1）的化合物或其盐具有 β3肾上腺素能受体激动剂活性，因此可用作糖尿病、肥胖症、高脂血症、抑郁症、胆结石或胆道蠕动亢进引起的疾病、活动过多引起的疾病、间歇性抑郁症的治疗剂和预防剂、胆结石或胆道过度活动引起的疾病、消化道过度活动引起的疾病、间质性膀胱炎、膀胱过度活动症或尿失禁，或作为伴随泪液减少的疾病的治疗和预防药物。